Inspire Medical Systems, Inc. Stock 12‑Month Price Target Cut to $52, Implies 16% Upside
Inspire Medical Systems, Inc. (INSP) has seen its average 12-month price target reduced from $53.08 to $52 by 13 analysts, with a range of $39 to $65 per share. This new target suggests a 16% potential upside from its May 21 closing price. Despite the target cut, the consensus rating from 16 analysts remains "Hold," with three "Buy" ratings, twelve "Hold" ratings, and one "Sell" rating.
MAY 8·GuruFocus→
INSP Maintained by Oppenheimer -- Rating Remains at Perform
Oppenheimer has maintained its 'Perform' rating on Inspire Medical Systems (INSP) as of May 7, 2026. Despite this cautious stance and recent price target adjustments from other firms, GuruFocus indicates that INSP is significantly undervalued with a GF Value™ of $241.35 against a current price of $45.57. The company exhibits strong financial health and growth potential but faces challenges in valuation and momentum.
APR 1·Insider Monkey▲
Hedge Funds View Inspire Medical (INSP) as One of the Best Small-Cap Healthcare Stocks
Hedge funds reportedly consider Inspire Medical Systems Inc. (NYSE: INSP) among the top small-cap healthcare stocks to buy. The company, which specializes in treatments for obstructive sleep apnea (OSA), recently received positive news regarding CMS reimbursement and new HCPCS codes, which analysts view as directionally positive despite some remaining uncertainties. Inspire Medical develops and markets neurostimulation technology for OSA treatment.
